Benzodiazepines are frequently encountered in forensic toxicology. A literature search was conducted to find a simple method using electron impact-gas chromatography-mass spectrometry (EI-GC-MS) to examine whole blood specimens for the most commonly encountered benzodiazepines in the United States. A recently published method was identified in the literature search and used as a starting point for development of a new procedure to be used for routine analysis of forensic toxicology case samples. The procedure was then developed and validated as a rapid and efficient method for the screening and quantitation of benzodiazepines in blood using liquid-liquid extraction and EI-GC-MS in selective ion monitoring mode. Materials and instrumentation common to most forensic toxicology laboratories were utilized while obtaining LODs from 5 to 50 ng/mL and LOQs of 50 ng/mL or less using 1 mL of sample. Target compounds were chosen based on availability and common use in the United States and include diazepam, desalkylflurazepam, nordiazepam, midazolam, oxazepam, temazepam, lorazepam, clonazepam, and alprazolam (relative elution order). The linear range (r 2 > 0.990) was validated from 50 to 1000 ng/mL for all analytes. The CV of replicate analyses at both 50 and 200 ng/mL was less than 4%. Quantitative accuracy was within ± 16% at 50 ng/mL and within ± 7% at 200 ng/mL. The validated method provides an efficient procedure for the quantitation of a broad range of the most common benzodiazepines in blood at meaningful limits of detection and quantitation using standard laboratory equipment and a small amount of sample.
Introduction
The benzodiazepines are encountered frequently in forensic toxicology as they are heavily prescribed and abused. Although benzodiazepines are commonly used in the United States, a simple, efficient, and sensitive method to analyze whole blood samples using electron impact-gas chromatography-mass spectrometry (EI-GC-MS) is quite difficult to find. In the comprehensive review of benzodiazepine analysis methods published between 1992 and 1997 by Drummer (1) , many different varieties of separation and detection options, except an EI-GC-MS method for testing whole blood for multiple benzodiazepines, are reported. This is most likely due to the much lower quantitation limits that have been reported using other detectors such as electron capture (ECD) (1) (2) (3) (4) and nitrogen phosphorus (NPD) (1, 5, 6) .
A survey of the literature was conducted using "*benzodiazepines/bl" as the search string in the PubMed database (www.pubmed.gov) for articles published between January 1997 and February 2008 relating to the quantitation of benzodiazepines in blood. Many of the recent efforts for the analysis of benzodiazepines used technology with less specificity, such as liquid chromatography (LC) with ultraviolet/visible spectrophotometry (UV/VIS) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , and/or complex and expensive LC instrumentation with single or tandem MS (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) . More recent GC methods typically involved tandem MS (41, 42) . These methods often had a limit of quantitation (LOQ) of single or even sub-nanograms per milliliter; however, forensic laboratories without access to this novel technology may be many years away from the practical application of such methods. Other published methods used more common instrumentation but still required specialized equipment (43) , involved solid-phase extraction (SPE), which used large volumes of solvents (44) , or analyzed few compounds from the drug class (45, 46) and therefore required separate procedures if multiple benzodiazepines were involved in a particular case analysis.
In this paper, a straightforward validation of a method adapted from one previously published by Gunnar et al. (47) is presented. The quantitation of benzodiazepines in whole blood method developed here involves a liquid-liquid extraction (LLE) of the benzodiazepines from 1 mL of human whole blood followed by on-column derivatization to form tertbutyldimethylsilyl (TBDMS) derivatives of those compounds containing an active hydrogen. Instrumental analysis was performed by EI-GC-MS in selective ion monitoring (SIM) mode.
Through development and validation an effort was made to maximize the efficiency, sensitivity, and relevance of the method by limiting the number of steps in the procedure while using materials, equipment, instrumentation, and practices that are common to most forensic toxicology laboratories. Considerations to accomplish this included the following: case sample size of no more than 1 mL, a common linear range for all target compounds, minimum extraction solvent evaporation time, on-column derivatization, standard MS tuning procedures (Agilent Chemstation Auto Tune), and minimal GC run time using a standard 30-m 5% diphenyldimethylsiloxane type column (DB-5MS) with helium as the carrier gas. With these specifications fulfilled, any forensic toxicology laboratory would be able to conduct internal validation, then implement and utilize this quantitation of benzodiazepines in whole blood method using existing resources.
Experimental

Materials
Human whole blood used in validation was obtained from various in-house sources, pooled and verified to be negative for all target analytes. Commercially prepared standards of each individual benzodiazepine (Cerilliant, Round Rock, TX; Alltech-Applied Science, State College, PA; and Lipomed, Cambridge, MA) were used to prepare working calibrator, working control, and internal standard solutions at 1 µg/mL in saline. Individual analytes used to prepare the working calibrator solution were from a different commercial source than those used for the working control solution.
Reagents and consumable supplies used for this validation procedure are as follows: hexane and sodium phosphate monobasic monohydrate (Na 2 Step Description 1. 1 mL negative whole blood for each standard and blank (×5) 2.
Prepare calibrators at 50, 100, 1000 ng/mL from the 1 µg/mL working calibrator solution 3.
Prepare a positive control at 200 ng/mL from the 1 µg/mL working control solution 4.
1 mL blood for each case sample 5.
Add 200 µL of the 1 µg/mL internal standard 6.
Add 1 mL 0.5 M pH 8 phosphate buffer 7.
Add 3 mL of butyl acetate, cap, and pulse vortex for~30 s 8.
Centrifuge at~2400 rpm for~10 min 9.
Transfer upper organic layer to a clean 10-mL conical centrifuge tube 10.
Evaporate to dryness under nitrogen at 75°C in Turbovap (approximate time = 15 min) 11.
Dissolve the residue in 0.5 mL of hexane saturated with acetonitrile 12.
Add 50 µL of acetonitrile and vortex mix 13.
Let the layers separate and aspirate the upper layer to waste 14.
Add 25 µL MTBSTFA w/1% TBDMCS and vortex mix 15.
Transfer to ALS vial with microinsert and cap for analysis 16.
Load method, verify instrument parameters, and run sequence The instrumentation used for EI-GC-MS SIM analysis was an Agilent 6890N series GC with a 5973N series mass spectrometer and a DB-5MS (Agilent) fused-silica capillary column with dimensions of 30 m × 0.25-mm i.d. and a 0.25-µm film thickness. Helium (ultra high purity) was used as the carrier gas. Table I is a summary of the quantitation of benzodiazepines in whole blood extraction method validated for casework. Calibrators were prepared in 1 mL of verified negative human whole blood using the 1 µg/mL working calibrator solution at 50, 100, and 1000 ng/mL in 15 mL NUNC disposable centrifuge tubes. A positive control was prepared at 200 ng/mL using the 1 µg/mL working control solution. An additional 1 mL of verified negative whole blood was used as a negative control (matrix blank). Internal standard solution (1 µg/mL) was then added to all samples (including the matrix blank) to reach a nominal concentration of 200 ng/mL. Next, 1 mL of 0.5 M phosphate buffer and 3 mL of n-butyl acetate were added to each sample. The centrifuge tubes were then capped and pulsevortex mixed for 30 s followed by centrifugation at approximately 2400 rpm for 10 min. The upper organic layer was transferred to a clean 10-mL borosilicate glass centrifuge tube with a 3-mL polyethylene transfer pipette. The extracts were evaporated to dryness under 20 psi of nitrogen in the TurboVap ® at 75°C for approximately 15 min. The resulting residue was dissolved in 500 µL of hexane saturated with acetonitrile. Fifty microliters of acetonitrile was added; the samples were vortex mixed and then allowed to separate. The upper hexane layer was then removed and discarded. Twenty-five microliters of MTBSTFA + 1% TBDMCS was added, vortex mixed, and then transferred to an automatic liquid sampler (ALS) microvial with insert. The vials were then capped and placed on the instrument for analysis.
Method
The extracts were analyzed on the GC-MS instrumentation described with a constant helium flow rate of 2 mL/min. The injection port temperature was maintained at 250°C with a pulsed splitless injection of 1 µL of the extract at 30 psi for 1 min followed by a purge flow of 50 mL/min at 0.9 min and 20 mL/min at 2 min. The initial oven temperature of 150°C was held for 0.6 min and then ramped at 40°C/min to 230°C followed by another ramp at 10°C/min to 310°C. A post run was then used with an oven temperature of 325°C for 3 min. The total run time, including the post run, was 13.6 min/sample. The MS source and quadrupole were maintained at 230°C and 150°C, respectively. The MS electron multiplier voltage was set to tune plus 200 (tuned using Agilent Chemstation Auto Tune). The SIM parameters are listed in Table II . Ions monitored (± 0.1 amu) were determined by analyzing a standard in Full Scan mode following the procedure outlined by the instrument manufacturer (48) . Quantitation was performed using the response ratio of the target ions for each analyte and corresponding deuterated internal standard. A typical total ion chromatogram from a 50 ng/mL calibrator is presented in Figure 1 . The corresponding extracted ion chromatograms for each target compound and internal standard are presented in Figure 2 .
Validation
The quantitation of benzodiazepines in whole blood method was validated by evaluating specificity, carryover, sensitivity, precision, accuracy, stability, linearity, and reportable range over four days of experiments. The general validation scheme is outlined in Table III and has been used to validate numerous methods within the Toxicology Unit at the Palm Beach County Sheriff's Office. The validation steps are not necessarily performed on sequential or even separate days. All instrumental and data analysis parameters were determined prior to the start of validation as part of method development and optimization.
Specificity was evaluated by analyzing human whole blood from multiple sources (including negative case samples) to ensure that no endogenous compounds interfered with the target analytes and corresponding internal standards. No interference
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Journal was observed from either the pooled verified negative whole blood used for validation or six case samples negative for benzodiazepines.
Carryover was evaluated by analyzing both a solvent blank (acetonitrile) which did not contain either target or internal standard compounds and an extracted whole blood blank which contained only the deuterated internal standards after the 1000 ng/mL calibrator. No carryover was observed for any compound (target and internal standard).
Sensitivity was evaluated by analyzing extracted standards
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Journal prepared from the working calibrator solution at levels of 5, 10, 25, 50, 100, 200, and 1000 ng/mL. Criteria used for evaluation of the limit of detection (LOD) required that qualifier ion ratios were within ± 20% of the target value set using the 100 ng/mL standard. Further criteria used to evaluate the limit of quantitation (LOQ) required that the observed concentration be within ± 30% of the expected value. Initial evaluation of the LOQ was performed using a linear least-squares calculated curve with the calibrator levels of 50, 100, and 1000 ng/mL (origin not included in curve). The curve was then expanded to include all levels between the observed LOQ and the 1000 ng/mL calibrator for verification of the quantitation value. For purposes of simplifying the validation, the LOQ for all compounds was administratively set to 50 ng/mL for all subsequent accuracy and precision studies. The concentrations listed in Table IV reflect the observed LOD and LOQ from Validation Step 1. Further validation may be performed to determine the accuracy and precision at the observed LOQ levels and expand the reportable range for those compounds that may be quantitated below 50 ng/mL. Precision was evaluated by analyzing replicates of standards prepared from the working control solution at two different levels (50 and 200 ng/mL). The levels were chosen to evaluate the precision at the LOQ (administratively set at 50 ng/mL for all compounds) of the quantitation of benzodiazepines in whole blood method as well as at the level to be used as a positive control for routine analysis (200 ng/mL). Three replicates of the positive controls at each level along with one negative control and calibrators prepared at 50, 100, and 1000 ng/mL were extracted on three separate days (Validation Steps 2-4). Within-run precision was evaluated by calculating the coefficient of variation (CV) of the replicate measurements of the positive controls from each day. Between-run precision was evaluated by calculating the CV of the mean values of the replicate measurements from each day. The quantitation of benzodiazepines in whole blood method demonstrated excellent precision at both levels with CVs for many compounds < 1% or < 2% and all within 4%. The precision data are summarized in Table IV. Accuracy is defined as the closeness of a measured result to the true value. Acceptable quantitative accuracy is ± 20% of the expected value (or ± 30% at or near the LOQ) (49) . Accuracy was determined by evaluating the percent error of the mean of replicate measurements at both 50 and 200 ng/mL over several days. Percent error was calculated by subtracting the expected from the observed concentration and dividing the result by the expected concentration. The value was then multiplied by (ng/mL) (ng/mL) ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL Diazepam 25 25 < 1% < 1% < 1% < 1% < 2% < 2% Desalkylflurazepam 10 10 < 1% < 1% < 2% < 1% < 11% < 2% Nordiazepam 25 25 < 1% < 1% < 3% < 1% < 7% < 5% Midazolam 25 25 < 2% < 2% < 2% < 1% < 8% < 6% Oxazepam 5 10 < 1% < 1% < 2% < 1% < 8% < 4% Temazepam 25 25 < 1% < 1% < 1% < 1% < 3% < 4% Lorazepam 5 50 < 2% < 1% < 1% < 1% < 16% < 7% Clonazepam 10 10 < 2% < 1% < 3% < 3% < 10% < 6% Alprazolam 50 50 < 3% < 4% < 2% < 2% < 2% < 5% 
Validation
Step Description
1
• Extract a matrix blank and calibrators (at least 3) at levels representing the anticipated range.
• Analyze by GC-MS, running the matrix blank after the highest calibrator.
• Determine suitable levels to use in routine analysis for calibrators (at least three).
Use these levels to generate a calibration curve (Update the Retention Time and Ion Ratios using the middle calibrator).
• Use the calibration curve to evaluate the other levels to determine the LOD and LOQ (if lower levels are analyzed). If only three calibrators are analyzed, then the lowest should be used as the LOD and LOQ.
• Determine a suitable level for the positive control to be used in routine analysis.
2
• Extract the calibrators, blank, and three replicates each of the positive controls, (one set at the LOQ, and one set at a higher concentration used for routine analysis).
• Analyze by GC-MS.
• Evaluate the positive controls against the calibration curve for precision and accuracy.
• Reserve one of the controls at each level for analysis on subsequent days.
3
• Repeat the extraction from Validation Step 2.
• Reanalyze the controls saved from Validation Step 2 for stability.
4
5
• Reanalyze case samples (both positive and negative) that have previously been tested by the current analytical methods (if applicable).
• Prepare proficiency samples for competency testing of analysts not involved in the validation of the method.
100%. The data summarized in Table IV are in terms of the absolute value of the greatest observed % error from data generated in Validation Steps 2-4. Most of the compounds demonstrated outstanding accuracy with a percent error of less than 10%. The largest observed percent error was < 16% for lorazepam at 50 ng/mL, still well within the acceptable range. Stability of the extracts was evaluated by reserving one positive control at each level from Validation Step 2. The positive controls were kept on the instrument and reanalyzed with the extracts from Validation Steps 3 and 4. The positive controls were compared to the calibration curve from the extraction on that day. The concentration for each of the analytes was within the acceptable range (± 20%) for each positive control on each day. The stability data for each compound are summarized in Table V . The total time evaluated spanned 7 days from Validation Step 2 to 4. Therefore, the extracts may be analyzed for at least 7 days after the extraction is performed.
The quantitation of benzodiazepines in whole blood method was linear for all compounds covering the entire routine calibration range of 50 to 1000 ng/mL. This was determined by evaluating the coefficient of determination (r 2 ) as well as the quantitative values for each calibrator. The r 2 was greater than 0.990 and the quantitative accuracy of each calibrator was within ± 20% for all compounds in all validation experiments.
Based on the administratively set LOQ and linearity of the quantitation of benzodiazepines in whole blood method, the reportable range for quantitative results was determined to be 50 to 1000 ng/mL. Samples outside this range may be reported semi-quantitatively (as < 50 or > 1000 ng/mL) or can be diluted appropriately and re-extracted.
Ten case samples were analyzed by this quantitation of benzodiazepines in whole blood method, and four had quantitative benzodiazepine results obtained by another method currently in use for casework. Alprazolam was present in three samples, and diazepam with nordiazepam was present in the fourth sample. All qualitative results obtained from the two methods for each case sample were identical. All quantitative results showed good correlation (quantitative values agreed within ± 10%). A summary of the results from the positive cases in the comparison study is presented in Table VI . Six case samples negative for benzodiazepines did not show any interference with the target analytes.
Discussion
During method development and optimization several variables were examined and are summarized in Table VII . Once the extraction procedure and instrumental parameters were optimized, validation of the method was conducted. The vali- dation scheme presented in Table III is intended to represent a simple, straightforward, systematic approach for determining the suitability of a method for its intended purpose. As stated earlier, one of the considerations in developing this quantitation of benzodiazepines in whole blood method was to obtain a common calibration range for all compounds. This was done to keep the method as simple as possible. However, some of the benzodiazepines (alprazolam, clonazepam, lorazepam, and midazolam) have therapeutic concentrations that can extend below the lowest calibrator (50 ng/mL). For clonazepam and midazolam, the observed LOQ was below 50 ng/mL, and further work will be conducted to examine quantitation down to the observed LOQ. Even though expanding the calibration range for these compounds may certainly be possible, it could be argued that the interpretation would be very much the same for a blood result of clonazepam reported as less than 50 ng/mL and a result of clonazepam at 15 ng/mL. This quantitation of benzodiazepines in whole blood method was also validated for qualitative screening of whole blood samples. The differences in the qualitative procedure involved an additional target analyte (flunitrazepam with an observed LOD of 50 ng/mL) as well as fewer internal standard compounds (temazepam-d 5 Flunitrazepam was not validated for quantitative analysis because of poor sensitivity and reproducibility below 100 ng/mL. In the screening procedure a positive control at 100 ng/mL and a whole blood blank were analyzed along with case samples. All other parameters were identical to the quantitation procedure. The purpose of the screening procedure was to provide a second testing method for those benzodiazepines that did not have sufficient cross-reactivity by a fluorescence polarization immunoassay (FPIA) panel (including benzodiazepines) used for casework. Other details of the screening procedure will not be discussed as part of this work.
Other blood procedures have included 7-aminoflunitrazepam as a target analyte as well as flunitrazepam. Only flunitrazepam was evaluated initially, as the parent compound is typically the more relevant for blood analysis of ante-mortem samples. However, the metabolite may be identified for a longer period of time after ingestion and therefore could be useful in sexual assault cases when no urine specimen is available. Further work will be conducted to evaluate the applicability of the method to 7-aminoflunitrazepam.
Both the screening and quantitation procedures are currently in use at the Palm Beach County Sheriff's Office for conducting analysis of benzodiazepines in antemortem whole blood from driving under the influence (DUI) and sexual assault cases.
Conclusions
The analysis of frequently encountered benzodiazepines in a forensic laboratory has been validated for whole blood samples using standard materials and equipment. This technique is sensitive, specific and reliable. The advantages over current methods include the ability to test for a broad range of the most common drugs encountered in the benzodiazepine class using a common calibration range without the need to purchase new equipment or change standard instrumental analysis parameters. Further method development and validation will be performed to evaluate the applicability of the method to the other benzodiazepines not evaluated in this study that are currently available in the United States (chlordiazepoxide, estazolam, quazepam, and triazolam). In addition, validation to include the newer sleep therapy drugs (zolpidem, zopiclone, and zaleplon) as demonstrated in the original methods by Gunnar et al. (43, 47) may also be evaluated.
